CB issuance terms amended, dilution reduced
비엘팜텍
065170
Signal Score
Historical Avg Return (5d)
+0.38%
Data Coverage
100%n=2330
Risk-adjusted indicator based on 2330 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
POSITIVE
Key Numbers
- • New CB Issuance Amount: 1.04B KRW
- • New CB Conversion Price: 848 KRW/Share
- • New CB Convertible Shares: 1,226,415 Shares
- • Previous Total Convertible Shares (incl. new CB): 3,995,645 Shares
- • Amended Total Convertible Shares (incl. new CB): 1,226,415 Shares
- • Previous Dilution Rate: 14.97%
- • Amended Dilution Rate: 4.39%
- • Call Option Size: Max 300M KRW (353,772 Shares at initial conversion price)
AI Analysis Summary
BL Pharmtech Corp. has amended its Material Fact Report regarding the issuance of convertible bonds. The key change involves the removal of market price-based conversion price adjustment clauses (resetting) and the specification of call option beneficiaries. The previous disclosure indicated 4.5B KRW in outstanding CBs, leading to a potential dilution of 14.97% (3,995,645 shares) based on 26,683,025 existing shares. The amended report, however, only lists the newly issued 1.04B KRW CB, resulting in a significantly reduced potential dilution of 4.39% (1,226,415 shares) against 27,913,793 existing shares. The call option size is specified as a maximum of 300M KRW, allowing designated parties (Kim Do-hoon, Kim Song-cheol, Jung Hyang-mi, related to the largest shareholder) to acquire up to 353,772 shares. The removal of downward conversion price adjustments is positive for existing shareholders, mitigating future dilution risk, while the overall dilution from the new CB is moderate.
Track Korean Market Signals — Free
Sign up free to access live disclosures, AI analysis, and event filters.
Public Beta · No credit card required
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.